Keytruda received FDA approval for cancer treatment, involving Merck KGaA.
4 reports, 3 independent
Updated Mon 00:00
Still developing
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Keytruda received FDA approval for cancer treatment, involving Merck KGaA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA accepts Keytruda copycat application amid concerns over anti-competitive deals.1 source
FDA granted approval for Keytruda, a cancer treatment, by Merck KGaA.1 source
Keep exploring
The entities involved
-
FDA
- The FDA is currently reviewing Medtronic's submission for its MiniMed 780G system, specifically regarding its use for Type 2 diabetes and label expansion into Europe.
- The Dietary Supplement Health and Education Act established the regulatory framework, with FDA oversight affecting the supplement industry.
-
Merck KGaA
German multinational science and technology company
Related events
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- FDA approved a new cancer drug in Massachusetts on October 21, 2026.
- NIH is funding research conducted by the National Cancer Institute (NCI) toward an FDA Investigational New Drug (IND) application.